These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 4th communication: Effects on gastrointestinal, urinary and reproductive systems and other effects. Arisawa H; Fukui K; Imai E; Fujise N; Masunaga H Arzneimittelforschung; 2002; 52(4):225-32. PubMed ID: 12040964 [TBL] [Abstract][Full Text] [Related]
44. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjörgen's syndrome. Iwabuchi Y; Masuhara T Gen Pharmacol; 1994 Jan; 25(1):123-9. PubMed ID: 7517901 [TBL] [Abstract][Full Text] [Related]
45. Primary Sjögren's syndrome: new clinical and therapeutic concepts. Ramos-Casals M; Tzioufas AG; Font J Ann Rheum Dis; 2005 Mar; 64(3):347-54. PubMed ID: 15498797 [TBL] [Abstract][Full Text] [Related]
47. Correlation between salivary secretion and salivary AQP5 levels in health and disease. Wang D; Iwata F; Muraguchi M; Ooga K; Ohmoto Y; Takai M; Mori T; Ishikawa Y J Med Invest; 2009; 56 Suppl():350-3. PubMed ID: 20224222 [TBL] [Abstract][Full Text] [Related]
52. Cevimeline (Evoxac) for dry mouth. Med Lett Drugs Ther; 2000 Aug; 42(1084):70. PubMed ID: 10932302 [No Abstract] [Full Text] [Related]
53. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. Fisher A; Brandeis R; Bar-Ner RH; Kliger-Spatz M; Natan N; Sonego H; Marcovitch I; Pittel Z J Mol Neurosci; 2002; 19(1-2):145-53. PubMed ID: 12212772 [TBL] [Abstract][Full Text] [Related]
54. M1, M3 and M5 muscarinic receptors stimulate mitogen-activated protein kinase. Wotta DR; Wattenberg EV; Langason RB; el-Fakahany EE Pharmacology; 1998 Apr; 56(4):175-86. PubMed ID: 9566019 [TBL] [Abstract][Full Text] [Related]
55. Cevimeline gargle for the treatment of xerostomia in patients with Sjögren's syndrome. Takagi Y; Kimura Y; Nakamura T Ann Rheum Dis; 2004 Jun; 63(6):749. PubMed ID: 15140789 [No Abstract] [Full Text] [Related]
56. Salivary enhancement: current status and future therapies. Atkinson JC; Baum BJ J Dent Educ; 2001 Oct; 65(10):1096-101. PubMed ID: 11699983 [TBL] [Abstract][Full Text] [Related]
57. Cevimeline co-treatment attenuates olanzapine-induced metabolic disorders via modulating hepatic M3 muscarinic receptor: AMPKα signalling pathway in female rats. Han M; Lian J; Su Y; Deng C J Psychopharmacol; 2022 Feb; 36(2):202-213. PubMed ID: 34694173 [TBL] [Abstract][Full Text] [Related]